Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierWe are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system that is specifically designed to be safe for use during MRI procedures and operates dependably in magnetic fields up to 15,000 gauss. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system.
In the company’s own words · 10-K filed Mar 6, 2026 · SEC EDGAR
Business segments
Q1 2026 · $22.0MThe company’s own SEC segment disclosure.
- US$18.0M82%
- Non Us$4.0M18%
IRADIMED CORPORATION (IRMD) reported revenue of $22M in Q1 2026 (quarter ended March 31, 2026), up 13% from the same quarter a year earlier. That came with a gross margin of 77% and net income of $5.8M (26% of revenue). For the full year FY2025, revenue was $84M (+14% year on year) and net income $22M. Its largest region in 2026-Q1 was US at $18M, 82% of the disclosed total, just ahead of Non Us at 18%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.